Is Hims Semaglutide Legit? The Honest 2026 Answer

"Legit" can mean two things: whether the seller is a real business that ships real medicine, and whether what arrives is the FDA-approved drug. FDA's materials answer the second question and describe what a trustworthy telehealth seller looks like. They do not rate individual companies.

Is compounding semaglutide still legal?

FDA's period of enforcement discretion for compounded semaglutide injection has ended. For state-licensed pharmacies and physicians it ended after a district court denied the compounders' preliminary injunction motion on 2025-04-24, and for outsourcing facilities FDA set the end at 2025-05-22 [2].

A pharmacy can still compound semaglutide for an individual patient who has a prescription [2]. The limits fall on copies. FDA says it does not intend to act against a compounder that fills four or fewer prescriptions per calendar month of a product that is essentially a copy of an approved drug, and it also permits a copy when the prescriber documents a change that produces a significant difference for that patient [2].

Outsourcing facilities are a separate case. They generally cannot compound a drug from bulk substances unless the substance appears on FDA's bulks list, and semaglutide is not on that list [2]. On 2026-04-30 FDA proposed to exclude semaglutide from the list, along with tirzepatide and liraglutide, finding no clinical need; comments were due 2026-06-29 and FDA says no final decision has been made [5].

What FDA says to look for in a telehealth seller

FDA's page on unapproved GLP-1 drugs says patients should get a prescription from their doctor and have it filled at a state-licensed pharmacy [1]. It lists these as telehealth red flags, including if a company [1]:

• makes claims such as the compounded drug being the same as an FDA-approved drug;
• does not require a screening and prescription by a licensed doctor before providing medicine;
• does not have a licensed doctor available to answer questions after you receive the medication;
• sends medicine that looks different from what was pictured or previously received, or that arrives in broken or damaged packaging or without instructions for use;
• makes spelling errors on the label or gives an incorrect pharmacy address, or puts a pharmacy name on the label that might be fraudulent.

On storage, FDA says injectable GLP-1 drugs require refrigeration and that it has received complaints of compounded products arriving warm or with inadequate ice packs; it recommends not using an injectable GLP-1 that arrives warm or with insufficient refrigeration [1]. For multi-dose vials, FDA generally recommends discarding the vial within 28 days after first use, even if medication remains, and using a new sterile needle and syringe for each dose [1].

FDA's stated position on when compounding is appropriate is narrow: compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug [1].

How a compounded vial differs from Wegovy

Compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [1]. FDA treats a compounded product as essentially a copy of a commercially available drug when the active ingredient is in a strength that is the same, similar or easily substitutable and the product is given by the same route as the approved drug [2]. Semaglutide sodium and semaglutide acetate salts are different active ingredients from the semaglutide in the approved products, and FDA says it is not aware of a lawful basis for using them in compounding [1]. Adding vitamin B12 does not automatically make a product different: FDA says a semaglutide-plus-B12 product may still be essentially a copy when it is given the same way and each strength is within 10% of the commercial product [2].

Dosing is another gap. FDA reports dosing errors with compounded injectable semaglutide, including patients measuring the wrong dose, clinicians miscalculating, and doses above the label [1].

What is known about the safety of the compounded product

FDA had received 990 adverse event reports for compounded semaglutide as of 2026-05-31 and says that number likely undercounts the real total [1].

The trial data on semaglutide come from the approved, manufactured products. In STEP 1, 1,961 adults with obesity, or overweight plus at least one weight-related condition, and without diabetes were enrolled; mean weight loss at 68 weeks was 14.9% with semaglutide 2.4 mg versus 2.4% with placebo [7]. The Wegovy, Ozempic, Rybelsus and Ozempic tablet labels carry a boxed warning about thyroid C-cell tumors seen in rodents at clinically relevant exposures; whether semaglutide causes these tumors in humans is unknown, and the drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [3][4][8].

The FDA-approved option

Wegovy injection is approved for weight reduction in adults and children 12 and older with obesity and in adults with overweight plus at least one weight-related condition, and Wegovy 25 mg daily tablets, approved on 2025-12-22, are for adults [3][6]. Ozempic is not a weight-loss drug; its indications are glycemic control, cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease, and kidney outcomes in type 2 diabetes with chronic kidney disease [4].

The bottom line

A compounded semaglutide prescription dispensed by a state-licensed pharmacy for an individual patient, within the limits FDA describes, is a real pathway [2]. It is not an FDA-approved substitute for Wegovy: FDA does not review compounded semaglutide before marketing, some compounded versions count as copies of the approved drug, and FDA had logged 990 adverse event reports for it by 2026-05-31 [1][2]. Whether a particular company follows the practices FDA describes is not something FDA's materials address.